Monotherapy

Latest Posts

Petosemtamab together with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with medical knowledge...

Market

Merus’ Petosemtamab Monotherapy Interim Knowledge Continues to Reveal Clinically Significant Exercise in 2L+ r/m HNSCC By Investing.com

First Launch of Part III Head-to-Head Scientific Research Knowledge of Ivonescimab versus Pembrolizumab in...

Market

Two Ivonescimab (PD-1/VEGF) Outcomes together with Part 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Remedy for PD-L1 Constructive NSCLC to Be Offered at WCLC...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V....

Market

Merus Presents Interim Information on MCLA-145 Monotherapy and in Mixture with Pembrolizumab on the 2024 ASCO ® Annual Assembly By Investing.com – Coin Trolly